MA31991B1 - Anticorps contre le virus de la grippe et procedes pour leur utilisation - Google Patents

Anticorps contre le virus de la grippe et procedes pour leur utilisation

Info

Publication number
MA31991B1
MA31991B1 MA32976A MA32976A MA31991B1 MA 31991 B1 MA31991 B1 MA 31991B1 MA 32976 A MA32976 A MA 32976A MA 32976 A MA32976 A MA 32976A MA 31991 B1 MA31991 B1 MA 31991B1
Authority
MA
Morocco
Prior art keywords
methods
influenza
antibodies
influenza virus
relates
Prior art date
Application number
MA32976A
Other languages
Arabic (ar)
English (en)
Inventor
Robert C Liddington
Wayne A Marasco
Jianhua Sui
Original Assignee
Dana Farber Cancer Inst Inc
Burnham Inst Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Burnham Inst Medical Research filed Critical Dana Farber Cancer Inst Inc
Publication of MA31991B1 publication Critical patent/MA31991B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)

Abstract

L'invention concerne des anticorps humains scfv et des anticorps monoclonaux qui neutralisent le virus de la grippe. L'invention concerne également des procédés de traitement et/ou de prévention d'une maladie ou d'un trouble associé à la grippe, comme la grippe aviaire. L'invention concerne également des procédés de vaccination d'un patient contre la grippe. Des procédés de diagnostic de maladies ou de troubles liés à la grippe et des procédés pour détecter la présence de la grippe dans un échantillon sont également décrits.
MA32976A 2007-12-06 2010-07-01 Anticorps contre le virus de la grippe et procedes pour leur utilisation MA31991B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US572507P 2007-12-06 2007-12-06
US9159908P 2008-08-25 2008-08-25
PCT/US2008/085876 WO2009079259A2 (fr) 2007-12-06 2008-12-08 Anticorps contre le virus de la grippe et procédés pour leur utilisation

Publications (1)

Publication Number Publication Date
MA31991B1 true MA31991B1 (fr) 2011-01-03

Family

ID=40796093

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32976A MA31991B1 (fr) 2007-12-06 2010-07-01 Anticorps contre le virus de la grippe et procedes pour leur utilisation

Country Status (18)

Country Link
US (3) US20110038935A1 (fr)
EP (3) EP3333187B1 (fr)
JP (5) JP6149213B2 (fr)
KR (1) KR20100115346A (fr)
CN (1) CN101970483A (fr)
AU (1) AU2008338691B2 (fr)
BR (1) BRPI0819971A2 (fr)
CA (1) CA2708221C (fr)
CO (1) CO6331300A2 (fr)
CR (1) CR11553A (fr)
EC (1) ECSP10010322A (fr)
IL (1) IL206156A0 (fr)
MA (1) MA31991B1 (fr)
MX (1) MX2010006148A (fr)
NZ (1) NZ586611A (fr)
RU (1) RU2010127156A (fr)
WO (1) WO2009079259A2 (fr)
ZA (1) ZA201004478B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2132312B1 (fr) 2007-03-27 2016-01-27 Sea Lane Biotechnologies,llc. Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps
RU2010127156A (ru) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
EP2698380A1 (fr) 2008-03-28 2014-02-19 Sea Lane Biotechnologies, LLC Neutralisation de molécules pour antigènes viraux
CA2736799A1 (fr) * 2008-08-25 2010-03-11 Burnham Institute For Medical Research Epitope conserve d'hemagglutinine, anticorps contre l'epitope et procedes d'utilisation
JP5396111B2 (ja) * 2009-03-12 2014-01-22 学校法人慶應義塾 インフルエンザ治療／予防薬
EP2413962A1 (fr) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Vaccins pour le virus influenza et leurs utilisations
WO2010130636A1 (fr) 2009-05-11 2010-11-18 Crucell Holland B.V. Molécules de liaison humaines pouvant neutraliser le virus de la grippe h3n2 et leurs utilisations
CA2761681A1 (fr) * 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Molecules neutralisantes dirigees contre les virus de la grippe
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
EP2528615B1 (fr) * 2010-01-27 2020-05-13 Massachusetts Institute of Technology Agents polypeptidiques techniques pour la neutralisation de la grippe à large spectre ciblée
AU2011217903B2 (en) 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP2545074A4 (fr) * 2010-03-08 2014-01-08 Celltrion Inc Anticorps monoclonaux humains dérivés de lymphocytes b humains et ayant une activité de neutralisation des virus de la grippe a
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
ES2687706T3 (es) * 2010-06-17 2018-10-26 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la gripe
JP2013540425A (ja) * 2010-08-03 2013-11-07 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション インフルエンザ感染の治療および制限のうち少なくとも一方を行うためのポリペプチド
AU2011289275A1 (en) * 2010-08-12 2013-02-21 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
CA2827301A1 (fr) * 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions et methodes de therapie et de diagnostic de la grippe
RU2491338C2 (ru) * 2011-06-30 2013-08-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский Институт гриппа" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "НИИ гриппа" Минздравсоцразвития России) Применение моноклональных антител для идентификации ямагатской или викторианской эволюционных линий вируса гриппа типа в, штамм гибридомы 4н7 для получения моноклональных антител, предназначенных для определения вирусов гриппа в ямагатской ветви, штамм гибридомы в/4н1 для получения моноклональных антител, предназначенных для определения вирусов гриппа в викторианской ветви
EP2736928B1 (fr) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Proteines "sur"-liantes dirigees contre erbb3
US9512202B2 (en) 2011-08-27 2016-12-06 University Of Zurich Multi-strain-reactive antibodies for therapy and diagnosis of influenza
IN2014CN02114A (fr) * 2011-09-20 2015-05-29 Sinai School Medicine
JP6371222B2 (ja) 2011-12-05 2018-08-08 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザの受動免疫用抗体
WO2013096828A1 (fr) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Protéines substitutives de liaison
CN109265541A (zh) 2012-05-10 2019-01-25 麻省理工学院 流感中和药剂
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CN103592436A (zh) * 2012-08-15 2014-02-19 华中农业大学 一种甲型h1亚型流感病毒抗体阻断elisa试剂盒及应用
CN103665153B (zh) * 2012-09-14 2016-03-16 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1e1
EP4154907A1 (fr) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Vaccins contre la grippe et utilisations associées
EP3003373A4 (fr) 2013-03-14 2016-10-19 Contrafect Corp Composition et méthodes fondées sur des anticorps neutralisants administrés par voie intranasale pour une efficacité thérapeutique améliorée
WO2014159960A1 (fr) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Anticorps contre l'hémagglutinine du virus de la grippe et utilisations correspondantes
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
EP3027640B1 (fr) * 2013-08-03 2018-03-07 Avatar Medical, LLC Protéines d'hémagglutinine de la grippe et méthodes associées
WO2015031268A1 (fr) * 2013-08-26 2015-03-05 Arizona Board Of Regents On Behalf Of Arizona State University Corps de synthèse à affinité élevée pour la grippe
JPWO2015068781A1 (ja) * 2013-11-06 2017-03-09 国立大学法人大阪大学 インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
RU2720282C1 (ru) 2014-02-04 2020-04-28 Контрафект Корпорейшн Антитела, подходящие для пассивной иммунизации против гриппа, и их композиции, комбинации и способы применения
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
WO2015143194A2 (fr) 2014-03-19 2015-09-24 Dana-Farber Cancer Institute, Inc. Restriction immunogénétique sur l'élicitation des anticorps
JP6525214B2 (ja) * 2014-06-03 2019-06-05 国立研究開発法人農業・食品産業技術総合研究機構 抗体またはその可変領域を含む抗体断片、抗原ポリペプチド、およびその利用
CN105301248A (zh) * 2014-07-24 2016-02-03 江苏维赛科技生物发展有限公司 金刚烷胺快速时间分辨荧光免疫层析定量检测试纸条
CN105301249A (zh) * 2014-07-24 2016-02-03 江苏维赛科技生物发展有限公司 金刚烷胺药物残留快速检测试纸条
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
KR20170090506A (ko) 2014-12-19 2017-08-07 다나-파버 캔서 인스티튜트 인크. 키메라 항원 수용체 및 이의 사용 방법
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
CN108135994B (zh) 2015-05-13 2022-01-25 宾夕法尼亚州大学信托人 Aav-介导的抗-流感抗体的表达及其使用方法
WO2017083627A1 (fr) 2015-11-13 2017-05-18 Visterra, Inc. Compositions et méthodes pour traiter et prévenir la grippe
WO2017124001A2 (fr) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center Anticorps de type récepteurs des lymphocytes t spécifiques pour des peptides dérivés de foxp3
WO2017147248A1 (fr) 2016-02-24 2017-08-31 Visterra, Inc. Formulations de molécules d'anticorps contre le virus de la grippe
US10233255B2 (en) 2016-04-25 2019-03-19 Sorrento Therapeutics, Inc. Antibody therapeutics that bind STAT3
WO2017218624A1 (fr) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Hémagglutinines du virus de la grippe et utilisations de celles-ci
CN106146657B (zh) * 2016-07-12 2020-07-17 晋明(天津)生物医药技术开发有限公司 广谱结合流感病毒a的重组抗体片段及其制备方法与应用
EP3526257A2 (fr) 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Plate-forme d'anticorps bispécifique tétravalent modulaire
US11250328B2 (en) 2016-10-26 2022-02-15 Cognizant Technology Solutions U.S. Corporation Cooperative evolution of deep neural network structures
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SG11201907611WA (en) 2017-02-28 2019-09-27 Univ Pennsylvania Influenza vaccines based on aav vectors
US11827906B2 (en) 2017-02-28 2023-11-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
US11507844B2 (en) 2017-03-07 2022-11-22 Cognizant Technology Solutions U.S. Corporation Asynchronous evaluation strategy for evolution of deep neural networks
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
EP3692997A4 (fr) * 2017-10-03 2021-09-29 Tokyo Metropolitan Institute of Medical Science Médicament contre la grippe
US11250314B2 (en) 2017-10-27 2022-02-15 Cognizant Technology Solutions U.S. Corporation Beyond shared hierarchies: deep multitask learning through soft layer ordering
WO2019118299A1 (fr) * 2017-12-13 2019-06-20 Sentient Technologies (Barbados) Limited Évolution de réseaux récurrents au moyen d'une programmation génétique
WO2019118290A1 (fr) 2017-12-13 2019-06-20 Sentient Technologies (Barbados) Limited Architectures évolutives pour l'évolution de réseaux neuronaux profonds
MA51681A (fr) 2018-01-26 2021-05-05 Regeneron Pharma Anticorps humains contre l'hémagglutinine de la grippe
US11527308B2 (en) 2018-02-06 2022-12-13 Cognizant Technology Solutions U.S. Corporation Enhanced optimization with composite objectives and novelty-diversity selection
US12033079B2 (en) 2018-02-08 2024-07-09 Cognizant Technology Solutions U.S. Corporation System and method for pseudo-task augmentation in deep multitask learning
WO2019178356A1 (fr) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Cellules spécifiquement modifiées, anticorps de modulation immunitaire de lymphocytes t et leurs procédés d'utilisation
CN108409841B (zh) * 2018-04-10 2021-06-04 北京康亿鸿科技发展有限公司 用于检测特异性过敏原IgE的单域结合蛋白及应用
EP3810634A4 (fr) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Polypeptides d'hémagglutinines du virus de la grippe en mosaïque et leurs utilisations
KR102143274B1 (ko) 2018-07-19 2020-08-10 전주대학교 산학협력단 이온화 및 나노화 미네랄을 함유하는 고병원성 조류독감 바이러스 소독제 조성물의 제조방법
US12282845B2 (en) 2018-11-01 2025-04-22 Cognizant Technology Solutions US Corp. Multiobjective coevolution of deep neural network architectures
CN109448781B (zh) * 2018-11-06 2021-09-14 云南大学 一种流感病毒抗原变化的预测方法
CN109608552A (zh) * 2018-12-26 2019-04-12 杭州亿米诺生物科技有限公司 一种小反刍兽疫重组融合蛋白及其制备方法和应用
CN111423507B (zh) * 2019-01-10 2022-04-15 中国科学院分子细胞科学卓越创新中心 广谱性中和流感病毒的全人抗体
US11481639B2 (en) 2019-02-26 2022-10-25 Cognizant Technology Solutions U.S. Corporation Enhanced optimization with composite objectives and novelty pulsation
US11669716B2 (en) 2019-03-13 2023-06-06 Cognizant Technology Solutions U.S. Corp. System and method for implementing modular universal reparameterization for deep multi-task learning across diverse domains
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
EP3948692A4 (fr) 2019-03-27 2023-03-29 Cognizant Technology Solutions U.S. Corporation Processus et système contenant un moteur d'optimisation à prescriptions assistées par substitut évolutives
US12026624B2 (en) 2019-05-23 2024-07-02 Cognizant Technology Solutions U.S. Corporation System and method for loss function metalearning for faster, more accurate training, and smaller datasets
US20220275061A1 (en) * 2019-07-12 2022-09-01 Contrafect Corporation Therapeutic protein formulations comprising antibodies and uses thereof
US12292944B2 (en) 2019-09-19 2025-05-06 Cognizant Technology Solutions U.S. Corp. Loss function optimization using Taylor series expansion
EP4073107A1 (fr) * 2019-12-11 2022-10-19 Visterra, Inc. Compositions et méthodes de traitement et de prévention de la grippe
WO2021201677A1 (fr) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions et procédés ciblant la grippe
US12099934B2 (en) * 2020-04-07 2024-09-24 Cognizant Technology Solutions U.S. Corporation Framework for interactive exploration, evaluation, and improvement of AI-generated solutions
US11775841B2 (en) 2020-06-15 2023-10-03 Cognizant Technology Solutions U.S. Corporation Process and system including explainable prescriptions through surrogate-assisted evolution
US12424335B2 (en) 2020-07-08 2025-09-23 Cognizant Technology Solutions U.S. Corporation AI based optimized decision making for epidemiological modeling
CN114181303B (zh) * 2020-09-14 2022-12-23 东莞市朋志生物科技有限公司 抗甲型流感病毒的抗体和试剂盒
EP4508077A1 (fr) * 2022-04-14 2025-02-19 Invisishield Technologies Ltd. Compositions pour prévenir ou traiter des infections par la grippe
CN114957479B (zh) * 2022-05-28 2024-06-18 浙江大学医学院附属第一医院 抗H1N1流感病毒双特异性中和抗体Bis-Hu11-1及其应用
WO2025019631A1 (fr) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Compositions immunogènes contenant un virus de la grippe a inactivé et un adjuvant oligonucléotidique cpg et leurs utilisations

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001513A1 (fr) 1986-08-28 1988-03-10 Teijin Limited Complexe d'anticorps cytocide et procede de production
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ　スケール　バイオロジー　コーポレイション 形質転換された微生物によるメラニンの製造
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
JPH07500820A (ja) 1991-09-05 1995-01-26 ユニバーシティ オブ コネティカット ポリヌクレオチド又はオリゴヌクレオチドの細胞への標的を定めた送達
AU668374B2 (en) 1991-12-10 1996-05-02 Dana-Farber Cancer Institute Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
EP0651805B1 (fr) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Procede de liaison intracellulaire de molecules cibles
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
JP3061960B2 (ja) * 1992-09-17 2000-07-10 寳酒造株式会社 抗ヒトインフルエンザウイルス抗体
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
EP0745134A1 (fr) 1994-02-22 1996-12-04 Danafarber Cancer Institute Systeme de liberation d'acide nucleique, son procede de synthese et ses utilisations
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
WO1997014809A2 (fr) 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Nouveaux vecteurs d'expression et procedes d'utilisation correspondants
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1999014353A2 (fr) 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Regulation a mediation intracorps de reactions immunitaires.
WO1999045959A1 (fr) 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Anticorps humanises et utilisations correspondantes
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
WO2000055335A1 (fr) 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Vecteurs lentiviraux pseudotypes et utilisations de ces vecteurs
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
AU2002351239A1 (en) 2001-12-04 2003-06-17 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2005005615A2 (fr) 2003-07-08 2005-01-20 Fox Chase Cancer Center Immunoconjugues du recepteur de type ii de l'hormone anti-mullerienne utiles pour detecter et traiter le cancer
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
WO2005123774A2 (fr) 2004-06-15 2005-12-29 Erol Fikrig Anticorps de polypeptides du virus du nil occidental
EP1784506B1 (fr) 2004-07-21 2010-08-25 Dana-Farber Cancer Institute, Inc. Vecteurs lentiviraux et utilisations associees
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
CN101115771B (zh) * 2005-02-03 2013-06-05 安迪拓普有限公司 人类抗体和蛋白质
KR20060089390A (ko) * 2005-02-04 2006-08-09 주식회사 중앙백신연구소 돼지 인플루엔자 바이러스ａ／ｓｗｉｎｅ／ｋｏｒｅａ／ｓ10/2004(ｈ1ｎ1) 및 이의백신
EP1871807B1 (fr) 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Anticorps contre cxcr4 et leurs procédés d'utilisation
CN101484182B (zh) * 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
JP2007000141A (ja) * 2005-05-25 2007-01-11 Tokyo Univ Of Science 完全ヒト抗体産生ハイブリドーマの作製方法、及び融合ミエローマ細胞
WO2007044695A2 (fr) 2005-10-07 2007-04-19 Dana-Farber Cancer Institute Anticorps diriges contre le sras-cov et procedes d'utilisation de ceux-ci
EP1979379B1 (fr) 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Anticorps contre l'anhydrase carbonique ix (g250), et procede d'utilisation correspondants
WO2009059032A2 (fr) 2007-10-30 2009-05-07 University Of Louisville Research Foundation, Inc. Utilisations et isolement de cellules souches de type embryonnaire très petites (vsel)
CA2637837A1 (fr) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Anticorps monoclonaux qui se lient a l'hemagglutinine de la sous-classe h5 du virus de la grippe aviaire et leurs utilisations
WO2007134327A2 (fr) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Anticorps neutralisants dirigés contre les virus de la grippe
EP2489728A1 (fr) 2006-06-15 2012-08-22 Neostem, Inc Procédure de traitement de cellules souches du sang périphérique
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
RU2010127156A (ru) * 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
WO2009086514A1 (fr) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humanisés et procédés d'utilisation
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
CN102216327A (zh) 2008-07-25 2011-10-12 生物医学研究所 中和抗甲型流感病毒抗体及其用途
CA2736799A1 (fr) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Epitope conserve d'hemagglutinine, anticorps contre l'epitope et procedes d'utilisation
WO2010130636A1 (fr) 2009-05-11 2010-11-18 Crucell Holland B.V. Molécules de liaison humaines pouvant neutraliser le virus de la grippe h3n2 et leurs utilisations
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Also Published As

Publication number Publication date
US20140011982A1 (en) 2014-01-09
CA2708221A1 (fr) 2009-06-25
KR20100115346A (ko) 2010-10-27
CR11553A (es) 2010-11-12
BRPI0819971A2 (pt) 2017-06-27
JP2017122087A (ja) 2017-07-13
EP2222701B1 (fr) 2017-11-01
WO2009079259A3 (fr) 2010-02-18
RU2010127156A (ru) 2012-01-20
ZA201004478B (en) 2011-12-28
CA2708221C (fr) 2017-07-25
US20110038935A1 (en) 2011-02-17
JP6149213B2 (ja) 2017-06-21
AU2008338691A1 (en) 2009-06-25
WO2009079259A2 (fr) 2009-06-25
WO2009079259A9 (fr) 2009-10-01
ECSP10010322A (es) 2010-09-30
EP3333187B1 (fr) 2022-06-22
IL206156A0 (en) 2010-12-30
JP2021176841A (ja) 2021-11-11
AU2008338691A2 (en) 2011-03-10
MX2010006148A (es) 2011-02-23
EP3333187A1 (fr) 2018-06-13
JP2015180619A (ja) 2015-10-15
JP2011506344A (ja) 2011-03-03
NZ586611A (en) 2012-09-28
US20180312575A1 (en) 2018-11-01
CN101970483A (zh) 2011-02-09
JP2019104736A (ja) 2019-06-27
AU2008338691B2 (en) 2015-01-22
EP2222701A2 (fr) 2010-09-01
CO6331300A2 (es) 2011-10-20
EP3524619A1 (fr) 2019-08-14
US9951122B2 (en) 2018-04-24

Similar Documents

Publication Publication Date Title
MA31991B1 (fr) Anticorps contre le virus de la grippe et procedes pour leur utilisation
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
MA35190B1 (fr) Anticorps anti-angptl3 et utilisations de ceux-ci
EA201690111A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
EP2860190A3 (fr) Anticorps monoclonal humain dérivé de cellules B humaines et ayant une activité neutralisante contre les virus de la grippe A
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
MA30337B1 (fr) Anticorps
TNSN07031A1 (fr) Anticorps diriges contre le peptide amyloide-beta et methodes pour leur utilisation
TNSN07401A1 (fr) Anticorps diriges contre le peptide amyloide-beta, et methodes pour leurs utilisations
EP2754671A3 (fr) Anticorps anti MIF
EP3552607A3 (fr) Inhibiteurs de syk d'imidazopyrazine
EP2987807A3 (fr) Anticorps dirigés contre tau phosphorylée
WO2006127861A3 (fr) Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
WO2008134569A3 (fr) Diagnostic et traitement de la rectocolite hémorragique chez la population portoricaine
WO2007044695A3 (fr) Anticorps diriges contre le sras-cov et procedes d'utilisation de ceux-ci
MA37670B1 (fr) Anticorps anti-transglutaminase 2
SG170804A1 (en) Pseudomonas aeruginosa outer membrane protein pa0427
BRPI0414688A (pt) tratamento de doença respiratória com anti-receptor de il-2
WO2006029142A3 (fr) Methodes et systemes de traitement de l'asthme et d'autres maladies respiratoires
ATE530667T1 (de) Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
GB0706558D0 (en) Diagnostic assay